Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Truveta’s groundbreaking study analyzing real-world use of GLP-1 receptor agonist (GLP-1 RA) therapies in adults with overweight or obesity has published in JAMA Network Open, offering critical ...

August 15, 2024, Paper: "Glucagon-like peptide 1 (GLP-1) receptor agonists and dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonists are among the most promising medical innovations of the ...

Zepbound is a brand name for a drug based on tirzepatide, a drug that includes both a GLP-1 agonist and a "gastric inhibitory polypeptide agonist." A GIP agonist promotes weight loss by affecting ...

Why NSAIDs Can Cause Ulcers NSAIDs can cause ulcers by interfering with the stomach's ability to protect itself from gastric acids. While these acids are vital to the digestive process, they can cause ...

As of Jan. 1, individual ACA plans and small-group plans from employers in the state include coverage for GLP-1s and gastric inhibitory polypeptide drugs, according to the North Dakota Insurance ...